Updated:
Valence Life Sciences
Valence Life Sciences is a life sciences investment firm focused on late-stage private and micro-cap public drug development companies. The firm manages the...
Overview
Valence Life Sciences is a life sciences investment firm focused on late-stage private and micro-cap public drug development companies. The firm manages the Valence Advantage Life Sciences Fund II, which invests in late-stage companies through a targeted strategy. Established in 2012 as a successor to Caxton Advantage Life Sciences Fund I, Valence Advantage Life Sciences is an independent entity.
General information
Firm type
Private Equity
Year founded
2012
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Sector focus
Frequently asked questions
What does Valence Life Sciences invest in?
Valence targets life sciences companies that use computation and artificial intelligence as core components of their therapeutic or diagnostic platforms. The firm invests across venture and growth stages, focusing on drug discovery platforms, digital health infrastructure, and precision medicine rather than traditional asset-centric biotech plays.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: